FOI REF: 26/720

6th November 2026

East Sussex Healthcare NHS Trust

Eastbourne District General Hospital
Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of May, June and July (or the latest 3 months available) with the treatments I have provided below?

As we are now in October, clarification was sought asking you to confirm if you required May, June and July for 2026 or if you would rather have the data for July, August and September and confirmation was received that you require the following:

Please note that the requested timeframe is correct.

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st December 2025 but did not receive any of the treatments between December 2025 and May 2026, they can be classed as a new patient for the purposes of this question.

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]	0	0	0
Adalimumab [All Biosimilar]	24	14	10
Etrasimod	0		0
Filgotinib	2		2
Golimumab [Simponi]	0	0	0
Golimumab [All Biosimilar]	0	0	0
Guselkumab	19	13	5
Infliximab [Remicade]	0	0	0
Infliximab [All Biosimilar]	40	17	16

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Mirikizumab	3	0	3
Ozanimod	0	[redacted]	0
Risankizumab	11	11	0
Tofacitinib	0	[redacted]	0
Upadacitinib	22	14	7
Ustekinumab [Stelara]	0	0	0
Ustekinumab [All Biosimilar]	42	25	13
Vedolizumab	8	2	6

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm